Exhibit 10.3.4


 


Certain identified information has been
excluded from the exhibit pursuant to Item 601(a)(6) of Regulation S-K or pursuant to Item 601(b)(10)(iv) because it is both not material
and is the type of information that the registrant treats as private or confidential. Redacted information is indicated by: [***]


 





 


UBC File: F16-05805


 


September 9, 2019


  


VIA EMAIL


 


Dr. Elliot Goldstein


President and CEO


ProMis Neurosciences, Inc.


Suite 200, 1920 Yonge Street


Toronto, ON


M4S 3E2


[***]


 


Dear Dr. Goldstein,


 


		Re:	Collaborative Research Agreement between The University of British Columbia (“UBC”)
and Vancouver Coastal Health Authority (“Hospital”) (UBC and Hospital collectively, the “Institution”) and ProMis
Neurosciences, Inc. (the “Sponsor”) effective April 1, 2016 and amended by Amendment No. 1 dated December 13, 2017, Amendment
No.2 dated July 5, 2018 and Amendment No.3 dated February 13, 2019 (the “Agreement”)



 


Amendment No. 4


 


The Institution and Sponsor have executed
the Agreement and hereby agree to amend the Agreement as follows:


 


Article 4.1 shall be revised and read as follows:


 


“4,1The
Parties understand and agree that, subject to Article 4.3, and excluding any intellectual property related costs under Section 7, the
total costs to the Sponsor hereunder will be $[***] (Canadian funds). The Parties acknowledge that
any budget categories that may be described in the Project are estimates only and that changes from category to category may be made at
the Institution’s discretion, The Sponsor will pay to UBC the amounts of the following due dates:


 


		1.	Amount already received by UBC		$[***]



 


		2.	Amount due upon signature of this Amendment No. 4	 	$[***]



 






     


     


    

 





		3.	December 1, 2019		$[***]



 


		4.	March 1, 2020	 	$[***]



 


		5.	June 1, 2020	 	$[***]



 


		6.	September 1, 2020	 	$[***]



 


		7.	December 1, 2020	 	$[***]



 


		8.	March 1, 2021	 	$[***]



 


		9.	June 1, 2021	 	$[***]



 


		10.	September 1, 2021	 	$[***]



 


		11.	December 1, 2021	 	$[***]



 


The Sponsor may make payments by wire transfer
to:


 


Pay Via: [***]


 


Pay to: [***]


 


Account number for Canadian dollars: [***]


 


Beneficiary: The University of British Columbia


 


Payment Details: [***]


 


UBC reserves the right to suspend work on all
Projects or to terminate all Projects and this Agreement by delivering written notice of same to the Sponsor if the Sponsor fails to pay
any invoiced amount within 30 calendar days from the due date.


 


The Sponsor will pay interest on all amounts owing
to UBC but not paid on the due date, at the rate of [***]% per annum, calculated annually not in advance. The interest accrues on the
balance of unpaid amounts from time to time outstanding, from the date on which portions of the amounts become due and owing until payment
in full.


 


All other terms and conditions of the Agreement
will remain in full force and effect and will continue for the duration of the Agreement. The Agreement and this Amendment No. 4 will
be read together and constitute one agreement.


 


This Amendment to the Agreement may be signed
in counterparts either through original copies or by facsimile or electronically each of which will be deemed an original and all of which
will constitute the same instrument.


 


(signature page follows)


 









    2 


     


    

 


	
    SIGNED FOR AND ON BEHALF of

    THE UNIVERSITY OF BRITISH COLUMBIA

    by its authorized signatory:

    

	 
	Name:	/s/	 
	Title:	 	 
	Date:	 	 
	 	 	 
	SIGNED FOR AND ON BEHALF of


THE UNIVERSITY OF BRITISH COLUMBIA


by its authorized signatory:


 






	 	 	 
	Name:	/s/	 
	Title:	 	 
	Date:	 	 
	 	 	 
	SIGNED FOR AND ON BEHALF of


VANCOUVER COASTAL HEALTH AUTHORITY


by its authorized signatory:



	 	 	 
	 	 	 
	Name:	/s/	 
	Title:	 	 
	Date:	 	 
	 	 
	SIGNED FOR AND ON BEHALF of


PROMIS NEUROSCIENCES, INC.


by its authorized signatory:









	 	 	 
	/s/ Elliot Goldstein	 
	Name:	Elliot Goldstein, MD	 
	Title:	President & CEO	 
	Date:	Oct. 7 2019	 


 












    Signature Page - 1 


     


    

 


	
    Acknowledged
by
	 

	 	 
	 	 
	
    Dr. Neil Cashman

    Principal Investigator

    Department of
    Neurology

    Date:
	 



 



    Signature Page - 2